BBOT – bridgebio oncology therapeutics, inc. (US:NASDAQ)
Stock Stats
News
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
BridgeBio Oncology Therapeutics (BBOT) had its price target raised by HC Wainwright from $27.00 to $29.00. They now have a "buy" rating on the stock.
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
BBOT to Participate in Upcoming Investor Healthcare Conferences
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Form 4 BridgeBio Oncology Thera For: Mar 10 Filed by: Beltran Pedro
Form 4 BridgeBio Oncology Thera For: Mar 10 Filed by: Mehra Uneek
Form 4 BridgeBio Oncology Thera For: Mar 10 Filed by: Ben Yong
Form 8-K Helix Acquisition Corp. For: Jan 22
Form 4 Helix Acquisition Corp. For: Jan 26 Filed by: Chen Bihua
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.